Get the tools used by (smart)2 investors.
SP500 0.6%DOW 0.7%FTSE 100 0.2%NIKKEI 0.4%OIL -2.8%GOLD -1.0%
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

Unlevered Free Cash Flow for ADMA Biologics Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

ADMA: ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United...

24.11 USD
Price
– USD
Fair Value
–
Upside
6.50 - 25.67
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on ADMA Biologics Inc's Unlevered Free Cash Flow:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-100 M-50 M0 K50 M100 M
Performance Summary
  • ADMA Biologics's latest twelve months unlevered free cash flow is 102.3 million
  • ADMA Biologics's unlevered free cash flow for fiscal years ending December 2020 to 2024 averaged -28.219 million.
  • ADMA Biologics's operated at median unlevered free cash flow of -58.317 million from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, ADMA Biologics's unlevered free cash flow peaked in December 2024 at 102.3 million.
  • ADMA Biologics's unlevered free cash flow hit its 5-year low in December 2021 of -107.1 million.
  • ADMA Biologics's unlevered free cash flow decreased in 2020 (-91.129 million, +31.6%) and 2021 (-107.1 million, +17.6%) and increased in 2022 (-58.317 million, -45.6%), 2023 (13.191 million, -122.6%), and 2024 (102.3 million, +675.6%).

How does ADMA Biologics Inc's Unlevered Free Cash Flow benchmark against competitors?

Hide this widget

We've identified the following companies as similar to ADMA Biologics Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

ADMA Biologics Inc Unlevered Free Cash Flow Benchmarks
NameTickerUnlevered Free Cash Flow
Geron CorporationNASDAQGS:GERN-199.2 M
CytomX Therapeutics IncNASDAQGS:CTMX-45.998 M
Cardiff Oncology IncNASDAQCM:CRDF-39.266 M
Trevena IncPINC:TRVN-25.113 M
HealthcareSECTOR:HLTH.US-11.553 M
Onconetix IncNASDAQCM:ONCO-7.358 M
Dyadic International IncNASDAQCM:DYAI-4.626 M
Biotest AktiengesellschaftPINC:BIES.F-
Kamada LtdNASDAQGS:KMDA26.978 M
ADMA Biologics IncNASDAQGM:ADMA102.3 M
Grifols, S.A.PINC:GIFL.F2.08 B
CSL LimitedPINC:CMXH.F2.825 B

Metric Usage: Unlevered Free Cash Flow

Hide this widget
fcf_unlev
Slug
number
Datatype
text
Format
current
Default Period
FY, Q, LTM
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Unlevered Free Cash Flow in the financials category include:

  • Net Income to Stockholders (Cont. Ops) - This item represents the net income or loss available to preferred and common stockholders and is arrived after adjusting net income to the company from continuing operations.
  • Prepaid Expenses - A current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
  • Unusual Items - Expense incurred for charges that are deemed to be special or non-recurring.
  • Policy Acq. And Underwriting Costs - This item represents the policy acquisition costs including deferred costs of various types of insurance businesses.
View Full List

Search for metric or datapoint

Unlevered Free Cash Flow

A cash flow measure that represents cash available to all providers of capital, including debt, equity, and hybrid capital. It is used to remove the i...

Definition of Unlevered Free Cash Flow

Hide this widget

The Unlevered Free Cash Flow is calculated as follows:

EBIT
(x) (1 - Marginal Tax Rate)
(=) NOPAT
(+) Depreciation and Amortization
(-) Capital Expenditures
(-) Investment in Net Working Capital
(=) Unlevered Free Cash Flow

Read more about nopat, depreciation & amortization, capital expenditures, and net working capital

Click the link below to download a spreadsheet with an example Unlevered Free Cash Flow calculation for ADMA Biologics Inc below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-239.5 M360.5 M960.5 M2.107 B04008001,200

The chart above depicts the distribution of unlevered free cash flow for companies operating in the Healthcare sector in the Developed economic region. Over 2,390 companies were considered in this analysis, and 2,299 had meaningful values. The average unlevered free cash flow of companies in the sector is 25.466 M with a standard deviation of 210.2 M.

ADMA Biologics Inc's Unlevered Free Cash Flow of 102.3 M ranks in the 91.1% percentile for the sector. The following table provides additional summary stats:

Unlevered Free Cash Flow In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,394
Included Constituents2,299
Min-265.5 M
Max2.08 B
Median-2.834 M
Mean25.466 M
Standard Deviation210.2 M

You can find companies with similar unlevered free cash flow using this stock screener.

All rights reserved. Terms Of Use